All In Biotech

Drug Trial Radar · NCT02265913

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

Last checked: Nov 19, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,076 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,076

Actual

Start

Oct 6, 2014

Primary completion

Apr 27, 2016

Study completion Nov 21, 2017

Sponsor

Lead sponsor
Padagis LLCIndustry
Sponsor type
Industry
First posted
Oct 16, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.

Conditions

  • Herpes Labialis

Interventions

  • Acyclovir 5 percent (Perrigo)Drug

  • Acyclovir 5 percent (Reference)Drug

  • Placebo creamDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lesion HealingTime frame: up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quality Clinical Research Inc

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.